CHICAGO, June 1 (Reuters) - Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.
Bluebird myeloma treatment delays cancer progression-trial
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться